This site is intended for U.S. healthcare professionals.

Indication
IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

EFFICACY

Watch a theoretical patient case and results from the pivotal trial.

Dr Hetty Carraway and Dr Daniel A Pollyea have been paid by Bristol Myers Squibb to participate in this video.

Dr Hetty Carraway is an Associate Professor of Medicine at the Cleveland Clinic.

Dr Daniel A Pollyea is an Associate Professor of Medicine and Clinical Director of Leukemia Services, Division of Hematology at the University of Colorado School of Medicine.

  1. Data on file, Celgene Corporation. Summit, New Jersey.